Oxytocin Solid-State Stabilization via Divalent Cations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oxytocin formulations are heat labile and require refrigeration, limiting their use in resource-poor settings, and existing dry powder formulations suffer from chemical instability issues such as dimer formation, which affects their efficacy and stability.
Innovation Solution
Incorporating a molar equivalent or greater amount of divalent cationic material, along with carbohydrates and hydrophobic amino acids, into disulfide bridge-closed ring-bearing polypeptides like oxytocin to stabilize the disulfide bridge and reduce dimer impurity formation in a solid-state form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If oxytocin is formulated as an injectable solution, then it can be administered with current medical infrastructure, but it requires refrigeration and sterile needles which are unavailable in resource-poor settings
Solution Approach 1:
The patent changes the physical state of oxytocin from liquid (injectable solution) to solid (dry powder formulation). This parameter change eliminates the need for refrigeration and sterile infrastructure, making the medication accessible in resource-poor settings while maintaining therapeutic efficacy through inhalation administration
Solution Approach 2:
The patent replaces the mechanical injection system (needles, syringes, refrigeration) with a respiratory delivery system (inhalation powder). This substitution eliminates complex medical infrastructure requirements and enables self-administration in communities without specialized healthcare facilities
2Temperature
If oxytocin is formulated as a dry powder, then it becomes heat stable and suitable for hot climates, but chemical instability issues such as dimer formation occur
Solution Approach 1:
The patent introduces divalent cations (such as calcium or magnesium) as intermediary substances that mediate between the oxytocin molecules. These cations bind to the disulfide bridges, preventing dimer formation and maintaining chemical stability while preserving heat stability properties
Solution Approach 2:
The patent creates a composite material system combining oxytocin with divalent cations and carrier molecules. This composite formulation maintains the heat stability benefits of dry powder while the divalent cation component prevents chemical degradation and dimer formation, achieving both temperature and chemical stability
3Stability of the object's composition
If the disulfide bridge is cleaved in oxytocin, then the molecule can reform, but dimer formation occurs instead which reduces therapeutic efficacy
Solution Approach 1:
The divalent cations act as intermediaries that bind to the disulfide bridges during cleavage events. This intermediary binding prevents the free thiol groups from reacting with other oxytocin molecules to form dimers, instead facilitating proper reformation of the cyclic structure and maintaining therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly enhances the physiochemical stability of oxytocin, reducing dimer impurities and maintaining therapeutic effectiveness, even in hot climates, by preventing disulfide bridge cleavage and promoting reformation within the same molecule, thus improving the formulation's heat stability and shelf life.
Implementation Method 1
providing in a solid-phase composite particle, a molar equivalent amount or greater of divalent cation to each molar amount of disulfide bridge-closed ring-bearing polypeptide
Data Source
AI summary
Methods of reducing chemical degradant formation, such as those resulting from dimer formation in disulfide bridge-closed ring-bearing polypeptides, such as oxytocin, in a solid-state; to heat stable pharmaceutical compositions having improved physio- or chemical stability, to inhalers and dosage forms of such compositions, to methods of production of and treatment of diseases and or conditions, such as post partum hemhorrage, with such compositions.